Dublin, Nov. 02, 2022 (GLOBE NEWSWIRE) — The “Cell & Gene Therapy Manufacturing Services Market Analysis by Type, by Indication, by Application, End user and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s providing.
The cell & gene remedy manufacturing companies market dimension is estimated to be USD 8.4 billion in 2021 and is predicted to witness a CAGR of 14.56% in the course of the forecast interval 2022-2029. The excessive charge of most cancers and different goal illnesses, rising investments in pharmaceutical R&D, investments in superior applied sciences by CDMOs, and growing partnerships and contracts between pharmaceutical firms and CDMOs are a few of the key drivers for the market development.
However, growing operational prices associated to cell and gene remedy manufacturing are anticipated to restrain the market development.
Based on kind, the market is bifurcated into gene remedy and cell remedy. In 2021, cell remedy section accounted for the very best income share as a result of improvement of recent applied sciences and product improvements which have allowed a wide range of cells, together with mesenchymal stem cells, dendritic cells, and T-cells, hematopoietic stem cells (HSC), pure killer cells, to deal with diseases and illnesses.
On the premise of Indication, the market is segregated into central nervous system problems, ophthalmology illnesses, cardiovascular illnesses, infectious illnesses, orthopaedic illnesses, oncology illnesses, and others. In 2021, the infectious illnesses section accounted for the biggest income share owing to the growth of cell remedy scientific trials due to the rise in infectious sickness prevalence.
Based on Application, the market is bifurcated into business manufacturing and scientific manufacturing. In 2021, the scientific manufacturing section accounted for the biggest income share as a result of rising variety of gene remedy scientific trials and the consistently increasing world pipeline of cell and gene therapies.
By End person
On the premise of finish person, the market is categorized into tutorial & analysis institutes and pharmaceutical & biotechnological firms. In 2021, the educational and analysis institutes section accounted for the very best share owing to growing authorities funding for analysis, and rising spending within the R&D sector in life sciences.
In 2021, North America area accounted for the very best income within the cell & gene remedy manufacturing companies market and is predicted to take care of its dominance in the course of the forecast interval. This is attributed to rising prevalence of most cancers and growing analysis effort in most cancers and stem cells, and important funding in biopharmaceutical analysis and improvement are fuelling market development. Furthermore, rising funding in pharmaceutical analysis and improvement is hastening regional market growth.
Segmentation: Cell & Gene Therapy Manufacturing Services Market Report 2021-2029
By Type (Revenue, USD Billion)
By Indication (Revenue, USD Billion)
By Application (Revenue, USD Billion)
By End person (Revenue, USD Billion)
By Region (Revenue, USD Billion)
Rest of Europe
Rest of APAC
Rest of LATAM
Middle East & Africa
Rest of MEA
Key Topics Covered:
1. Research Methodology
2. Introduction: Cell & Gene Therapy Manufacturing Services
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Cell & Gene Therapy Manufacturing Services Market
7. Market Analysis by Type
8. Market Analysis by Indication
9. Market Analysis by Application
10. Market Analysis by End person
11. Regional Market Analysis
12. North America Cell & Gene Therapy Manufacturing Services Market
13. Europe Cell & Gene Therapy Manufacturing Services Market
14. Asia Pacific Cell & Gene Therapy Manufacturing Services Market
15. Latin America Cell & Gene Therapy Manufacturing Services Market
16. MEA Cell & Gene Therapy Manufacturing Services Market
17. Competitor Analysis
18. Company Profiles
19. Conclusion & Recommendations
Thermo Fisher Scientific Inc. (US)
Merck KGaA (Germany)
Charles River Laboratories (US)
Catalent Inc. (US)
WuXi AppTec (China)
Takara Bio Inc. (Japan)
NIKON CORPORATION (Japan)
FUJIFILM Holdings Corporation (Japan)
F. Hoffmann-La Roche Ltd. (Switzerland)
Oxford Biomedica plc (UK)
Cell and Gene Therapy Catapult (UK)
The Discovery Labs LLC (US)
JRS PHARMA (Germany)
ABL Inc. (US)
Porton Biopharma Limited (England)
elyn Biosciences (US)
Commercializing Living Therapies (Canada)
Anemocyte Srl (Italy)
For extra details about this report go to https://www.researchandmarkets.com/r/v0yca5
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
#Cell #Gene #Therapy #Manufacturing #Services #Market #Grow #Annually